General
Preferred name
MITOMYCIN
Synonyms
mitomycin C ()
Mytozytrex,NSC-26980 ()
MitoExtra ()
Mitonco ()
Mutamycin ()
7-Amino-9.alpha.-methoxymitosane ()
Ametycine ()
Mitomycinum ()
MMC ()
Mit-C ()
Mito-C ()
Ametycin ()
Mitomycin C from Streptomyces caespitosus ()
Mitozytrex ()
NSC-26980 ()
Mitomycin-c ()
Ugn-102 ()
UGN-101 ()
Jelmyto ()
Mitomycin C ()
Mitocin-c ()
Muamycin ()
Mitosol ()
Mytozytrex ()
P&D ID
PD003405
CAS
50-07-7
144085-53-0
1404-00-8
Tags
prodrug
natural product
drug
available
Approved by
PMDA
FDA
First approval
1981
Drug Status
approved
Drug indication
Gastrointestinal cancer
Antineoplastic
Solid tumour/cancer
Breast cancer
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Mitomycin C is an antineoplastic drug, with DNA alkylating activity. It is one of the mitomycin family of compounds, isolated from Streptomyces caespitosus or Streptomyces lavendulae. (GtoPdb)
DESCRIPTION DNA crosslinker (Informer Set)
DESCRIPTION DNA synthesis inhibitor (Tocris Bioactive Compound Library)
Cell lines
693
Organisms
6
Compound Sets
19
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
Informer Set
LINCS compound set
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
NPC Screening Collection
ReFrame library
Tocris Bioactive Compound Library
Welcome Trust Cancer Drugs
External IDs
53
Properties
(calculated by RDKit )
Molecular Weight
334.13
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
3
Rotatable Bonds
3
Ring Count
4
Aromatic Ring Count
0
cLogP
-1.65
TPSA
146.89
Fraction CSP3
0.53
Chiral centers
4.0
Largest ring
6.0
QED
0.41
Structural alerts
1
quinone_A(370)
[!#6&!#1]=[#6]-1-[#6]=,:[#6]-[#6](=[!#6&!#1])-[#6]=,:[#6]-1
PAINS Family A
Custom attributes
(extracted from source data)
Compound status
FDA
Pathway
DNA replication
DNA Damage/DNA Repair
Target
DNA crosslinker
DNA synthesis
Primary Target
Apoptosis Inducers
MOA
DNA/RNA Synthesis inhibitor
DNA alkylating agent, DNA synthesis inhibitor
Indication
pancreatic cancer, gastric adenocarcinoma
Therapeutic Class
Anticancer Agents
Source data